Morgan Stanley raised their stock price forecast on Berkeley Lights to $80 from $65, assigning an “Equal-weight” rating and said the leading digital cell biology company’s top-line earnings beat in its first quarter was driven by robust system installs to cell therapy and CRO/CDMO customers and a strong recovery in recurring revenue of the expanding installed base.
On Thursday, Berkeley Lights reported total revenue of $18.2 million for the third quarter, representing a 16% increase over the same period in 2019 and a 72% increase compared to the second quarter of 2020. That was higher than the Wall Street estimate of $15.3 million.
Berkeley Lights’ shares closed 4.59% higher at $95.00 on Friday; the stock is up over 85% since it began trading on the Nasdaq Global Select Market on July 17, 2020.
For more information please refer to the original article: https://www.fxempire.com/forec...
تم التحرير 16 Nov 2020, 10:14
إخلاء المسؤولية: الآراء الواردة هنا تعبر فقط عن رأي الكاتب، ولا تمثل الموقف الرسمي لـ Followme. لا تتحمل Followme مسؤولية دقة أو اكتمال أو موثوقية المعلومات المُقدمة، ولا تتحمل مسؤولية أي إجراءات تُتخذ بناءً على المحتوى، ما لم يُنص على ذلك صراحةً كتابيًا.
اترك رسالتك الآن